Aspirin: Bark, Bayer, and a Two-Carbon Acetyl Group

A drug older than writing

Around 400 BC, Hippocrates instructed Greek women to chew willow bark to relieve the pain of childbirth. He didn’t know why it worked. He just observed that it did, and the practice passed into Western medicine more or less unchanged for the next two thousand years.

Sumerian tablets from 4000 years before Hippocrates contain similar prescriptions. Egyptian papyri from 1550 BC list willow. The Cherokee chewed willow for headaches; the Hottentots of South Africa used a different willow species for the same purpose. Every continent with willow trees, more or less independently, figured out that the bark did something useful for pain and fever.

The molecule responsible — salicin — was first isolated in 1828 by the German pharmacist Johann Buchner, then purified the following year by the Frenchman Henri Leroux. A decade later, in 1838, the Italian chemist Raffaele Piria showed that salicin could be converted to salicylic acid, and that salicylic acid was the actual active analgesic.

It was also a stomach destroyer. Pure salicylic acid is so harsh that long-term use causes severe gastric ulcers. Doctors used it cautiously through the 19th century, knowing it worked but watching their patients bleed internally.

What was needed was a chemical modification that kept the analgesic effect but smoothed the rough edge.

Bayer, 1897

The standard story is that a Bayer chemist named Felix Hoffmann synthesized acetylsalicylic acid in 1897 to ease his arthritic father’s pain. The truth is messier. The synthesis had been described by a French chemist, Charles Gerhardt, back in 1853 — but Gerhardt’s product was impure and the procedure unreliable. Hoffmann simply produced the first pure, scalable batch using a cleaner acetylation method.

There is also strong documentary evidence that the synthesis was actually directed by Hoffmann’s supervisor, a Jewish chemist named Arthur Eichengrün, whose contribution was systematically erased from Bayer’s official histories during the Nazi era. Eichengrün spent World War II in Theresienstadt and tried, after liberation, to reclaim credit. The German chemistry community largely ignored him.

Whoever did the work, the result was the same: a single chemical modification turned a harsh medieval remedy into a manageable drug. Bayer trademarked the name Aspirin in 1899 and began selling it to physicians as a powder. Within a decade it was the most widely used drug in the world.

What the two-carbon modification actually does

Salicylic acid is C₇H₆O₃: a benzene ring with a carboxyl group on one carbon and a hydroxyl on the neighboring one. The free hydroxyl is the problem. It makes the molecule a strong organic acid that irritates the stomach lining on direct contact.

Aspirin (C₉H₈O₄) is the same molecule with an acetyl group — a small CH₃-CO- unit — attached to that hydroxyl. The hydroxyl is now an ester. The molecule is much less acidic, much gentler on stomach tissue.

Once the aspirin enters the bloodstream, the body’s esterases slowly hydrolyze the acetyl group back off, releasing salicylic acid — the original active drug. So acetylation acts as a kind of biological time-release wrapping. You take the gentler ester; your body unwraps it to the active acid wherever it ends up.

That part of the story was well-understood by 1900. The other half — what acid does, on the molecular level, in your tissues — took another 70 years.

What John Vane figured out in 1971

For decades after the synthesis, aspirin’s mechanism was a complete mystery. It killed pain, it reduced fever, it reduced inflammation. Nobody could say how.

In 1971, the British pharmacologist John Vane showed, in a series of careful tissue experiments, that aspirin worked by inhibiting an enzyme that synthesizes a small class of signaling molecules called prostaglandins.

Prostaglandins are local hormones. They’re made on demand at sites of tissue damage, infection, or stress, and they do three useful things — and several uncomfortable ones. They cause local inflammation (recruiting immune cells). They sensitize pain receptors (so the wound hurts and you protect it). They raise body temperature (creating fever to slow pathogens). Without prostaglandins, no inflammation, no fever, much less pain.

The enzyme that makes them — eventually named cyclooxygenase, or COX — was Vane’s target. Aspirin doesn’t just slow COX. Aspirin acetylates a specific serine residue (Ser-530) in COX-1’s active site, transferring its acetyl group to the enzyme. The enzyme is now permanently disabled. It can never make another prostaglandin.

This is a covalent, irreversible inhibition — the same mechanism by which penicillin disables DD-transpeptidase. Aspirin is, mechanistically, an enzyme assassin.

Vane won the Nobel Prize in 1982 for this work.

A funny side effect

Because aspirin permanently kills COX-1 in any cell it touches, and because the cells most exposed to aspirin in your bloodstream are platelets, aspirin permanently kills COX-1 in your platelets.

Platelets are anucleate — they can’t make new proteins. So when a platelet loses its COX-1, it can’t make a prostaglandin called thromboxane A2, which is what platelets use to clump together and form clots.

A platelet exposed to aspirin is functionally crippled for its entire 7-to-10-day lifespan.

This is why a single 81 mg “baby aspirin” daily, used worldwide as cardiovascular prophylaxis, works: it permanently disables a fraction of your platelet population. Over time, equilibrium settles so that always-aspirinated platelets dominate, your blood is harder to clot, and you’re at lower risk of heart attack and stroke from clot-induced arterial blockage.

You’re also at higher risk of bleeding. This is the trade-off cardiologists wrestle with every day. As of 2019, the major guidelines walked back routine aspirin prophylaxis for healthy older adults — for many people, the bleeding risk now appears to slightly exceed the cardiovascular benefit. But for someone who has already had a heart attack or a stroke, daily low-dose aspirin remains one of the cheapest, best-proven secondary prevention interventions in all of medicine.

A warning that took 50 years

In the 1960s and 70s, pediatricians began noticing a pattern: children who were given aspirin during viral infections (especially flu and chickenpox) occasionally developed a catastrophic syndrome of brain swelling and liver failure. The death rate was around 30%. Survivors often had permanent brain damage.

This became known as Reye’s syndrome, after Australian pathologist Douglas Reye, who first described it systematically in 1963. The link to aspirin was confirmed by epidemiology in the early 1980s. By 1986, aspirin packaging in the US carried a clear warning: not for children or teenagers with viral illness (modern guidance is generally “under 16”).

Aspirin use in children fell to near zero. Reye’s syndrome cases dropped from 555 cumulative cases reported in 1979–80 (the peak) to fewer than a handful per year by the mid-1990s. A textbook case of a slow-emerging side effect, properly tracked, properly responded to.

This is why your bottle of children’s painkiller is acetaminophen or ibuprofen, not aspirin. Aspirin remains an adult drug, almost exclusively.

The molecule’s odd second career

Beyond pain, fever, inflammation, and cardiovascular prophylaxis, aspirin has been studied — sometimes credibly, sometimes not — in a startling range of contexts. Daily aspirin lowers the lifetime risk of colorectal cancer by around 30% in long-term cohort studies; the mechanism is probably the same COX inhibition acting on inflammatory tumor microenvironments. Aspirin reduces preeclampsia risk in pregnancy when started early in the second trimester. It improves outcomes after some heart surgeries. It is currently in clinical trials for several cancers.

It is also, when overdosed, lethal. Salicylate poisoning produces metabolic acidosis, respiratory failure, and coma. Aspirin overdose kills roughly 40–70 Americans a year. The same drug that prevents heart attacks at 81 mg can kill at 30 grams.

This is the recurring theme of every story in this library: the molecule isn’t good or bad. The dose, the patient, the context, the timing — those are what determine whether a chemical helps or kills. Aspirin happens to span more orders of magnitude on that scale than almost any other drug, which is why it ended up in every household in the developed world.

50,000 tonnes per year

Global aspirin production today is around 35,000–40,000 tonnes per year. That’s tens of billions of tablets. Bayer’s original 1899 trademark on the name Aspirin still holds in Germany, France, and a handful of other countries; in the US, the trademark was forfeited as part of the Treaty of Versailles after World War I, and “aspirin” became a generic word in the English-speaking world.

The other piece of Versailles trivia worth knowing: as reparations for the war, Bayer lost the rights to its other most-famous trademark — Heroin. Both molecules have the same heritage: Bayer’s industrial chemistry program in the 1890s, treating coughs and pain with everything they could synthesize. One became the household remedy. The other became one of the worst public health disasters of the 20th century.

A two-carbon acetyl group was the difference between them. Aspirin is acetylsalicylic acid. Heroin is diacetylmorphine. Same trick, different starting material, very different consequences.

The next time you take an aspirin for a headache, remember: you’re swallowing a 2400-year-old drug that we only understood mechanistically 50 years ago, made gentler by a single acetylation, working by covalently shutting down an enzyme in your tissues, in a dose carefully calibrated so it kills your pain without killing you.

---

The aspirin molecule has its own 3D page in the library — rotate it, find the small acetyl group that turned salicylic acid from a stomach-shredder into a household drug, download the structure file. It also has its own bouncing wallpaper.